PT  - JOURNAL ARTICLE
AU  - Li, Xintao
AU  - Chan, Jeffrey Shi Kai
AU  - Guan, Bo
AU  - Peng, Shi
AU  - Wu, Xiaoyu
AU  - Zhou, Jiandong
AU  - Hui, Jeremy Man Ho
AU  - Lee, Yan Hiu Athena
AU  - Satti, Danish Iltaf
AU  - Tsang, Shek Long
AU  - Wu, Shouling
AU  - Chen, Songwen
AU  - Tse, Gary
AU  - Liu, Shaowen
TI  - Triglyceride-glucose index and the risk of heart failure: evidence from two large cohorts and a Mendelian randomization analysis
AID  - 10.1101/2022.06.28.22277033
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.28.22277033
4099  - http://medrxiv.org/content/early/2022/06/29/2022.06.28.22277033.short
4100  - http://medrxiv.org/content/early/2022/06/29/2022.06.28.22277033.full
AB  - Background The relationship between triglyceride-glucose (TyG) index, an emerging marker of insulin resistance, and the risk of incident heart failure (HF) was unclear. This study thus aimed to investigate this relationship.Methods Subjects without prevalent cardiovascular diseases from the prospective Kailuan cohort (recruited during 2006-2007) and a retrospective cohort of family medicine patients from Hong Kong (recruited during 2000-2003) were followed up until December 31st, 2019 for the outcome of incident HF. Separate adjusted hazard ratios (aHRs) summarizing the relationship between TyG index and HF risk in the two cohorts were combined using a random-effect meta-analysis. Additionally, a two-sample Mendelian randomization (MR) of published genome-wide association study data was performed to assess the causality of observed associations.Results In total, 95,996 and 19,345 subjects from the Kailuan and Hong Kong cohorts were analyzed, respectively, with 2,726 cases (2.8%) of incident HF in the former and 1,709 (7.0%) in the latter. Subjects in the highest quartile of TyG index had the highest risk of incident HF in both cohorts (Kailuan: aHR 1.23 (95% confidence interval: 1.09-1.39), PTrend <0.001; Hong Kong: aHR 1.21 (1.04-1.40), PTrend =0.007; both compared with the lowest quartile). Meta-analysis showed similar results (highest versus lowest quartile: HR 1.22(1.11-1.34), P<0.0001). Findings from MR analysis, which included 47,309 cases and 930,014 controls, supported a causal relationship between higher TyG index and increased risk of HF (odds ratio 1.27(1.15-1.40), P<0.001).Conclusion A higher TyG index is an independent and causal risk factor for incident HF in the general population.What is new?In 115,341 subjects from two large cohorts in China, an elevated triglyceride-glucose (TyG) index was independently associated with an increased risk of incident heart failure (HF).Two-sample Mendelian randomization analysis based on published genome-wide association studies found significant association between genetically determined TyG index and the risk of HF.Together, these findings suggest that a higher TyG index is an independent and causal risk factor of incident HF in the general population.What are the clinical implications?The TyG index may facilitate recognition of individuals at elevated risk of incident HF and allow early preventive interventions.The demonstrated causal effect of TyG index on incident HF warrants further research to fully understand the underlying mechanisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (Grant No. 81970273).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee at the Kailuan General Hospital and the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors